December 2015 Newsletter

December 9, 2015:

US Ophthalmic Procedures Grow 3.0 Percent in Q3-2015

Cataract volume outpaced historical trends, while refractive surgery missed expectations.

December 9, 2015:

Medicare Fee Cuts Dominate Discussion at 2015 AAO Meeting

IRIS registry, US health policy also garner attention at biggest ophthalmic meeting of the year.

December 9, 2015:

Ophthalmology Innovation Summit Draws Record Crowd

Top executives discussed their decision process for developing new technology in house or acquiring it.

December 9, 2015:

2015 AAO Meeting: Experts Still Find Value in FLCS but Decry Claims of Better Outcomes for Patients

Five of seven panelists at the ‘Cutting Edge’ symposium said they were not using FLCS technology, but they feel it has potential.

December 9, 2015:

2015 AAO Meeting: Managing Complications of Cataract Surgery is Focus of Many Sessions

Product launches included Abbott’s introduction of its Whitestar Sovereign Pro; several early-stage companies showed manual capsulotomy devices.

December 9, 2015:

2015 AAO Meeting: PC-IOL Sessions Highlight New Options for EDOF, Low-Add Multifocal Lenses

Speakers described next-generation accommodating IOLs such as the Alcon/Google battery-operated and LensGen accommodating IOLs.

December 9, 2015:

2015 AAO Meeting: Speakers Discuss Refractive Outcomes with KAMRA Inlay, Epi-On CXL Procedures

Alcon unveils Contoura Vision, the latest advancement in its WaveLight refractive portfolio.

December 9, 2015:

2015 AAO Meeting: Carl Zeiss Meditec Files Final PMA Module with FDA for SMILE Treatment of Myopia

The company expects an FDA advisory panel meeting will be scheduled in the coming months.

December 9, 2015:

2015 AAO Meeting: Latest Diagnostic Tools Providing a New Level of Detail to Doctors

Retina specialist says new terminology is needed to describe some of the findings.

December 9, 2015:

2015 AAO Meeting: New Gene, Stem Cell, Combo Therapies Highlight Retinal Pharma, Biotech

In anti-fibrosis pilot study, pretreatment with Fovista showed promise in patients with resistance to VEGF inhibition alone.

December 9, 2015:

2015 AAO Meeting: Retinal Surgical Equipment Options Continue to Expand; Doctors Debate Value

Only 21 percent of the audience at one session saw routine use of intraoperative OCT for macular surgery as useful.

December 9, 2015:

2015 AAO Meeting: Retinal Implant Companies Provide Updates on Argus II, Alpha IMS

Argus II is now being implanted at 31 centers worldwide; Alpha IMS team is discussing design of US feasibility study.

December 9, 2015:

2015 AAO Meeting: Shire’s Commitment to Ophthalmology Deepens, as Lifitegrast Refiling Nears

The company is targeting Q3-2016 for FDA approval.

December 9, 2015:

2015 AAO Meeting: Michael Kass, MD, Reviews 20 Years of OHTS, Readies for 20 More

The study is among Kass’ many contributions to glaucoma research.

December 9, 2015:

AMA Seeks Ban on Consumer Ads for Prescription Drugs, Medical Devices

The group said such commercials boost demand for expensive—and sometimes inappropriate—treatments, despite the clinical effectiveness of less costly alternatives.

December 9, 2015:

Pfizer, Allergan Agree to $160 Billion Merger, Sidestep US Tax Rules

Brent Saunders will become president and chief operating officer of the combined entity

December 9, 2015:

Sun Pharmaceutical Finalizes InSite Vision Acquisition

Sun Pharma intends to use the acquisition to expand its eye care business in the US.

December 9, 2015:

Alphaeon’s Acquisition of LENSAR Valued at $59 Million

LENSAR developed the first femtosecond cataract laser that enabled automation of several elements of cataract surgery.

December 9, 2015:

Valeant CEO Says Debt Repayment is Priority

The firm reported long-term debt of $30.2 billion as of Sept. 30.

December 9, 2015:

Alcon’s Weaker Segments May be Sold Following ‘Deep Analysis’ of Firm

Novartis will unveil in January plans to spur growth in its eye care division.

December 9, 2015:

Genentech to Share OUS Rights for Fovista with Novartis

A pre-existing agreement between the two firms made the move possible.

December 9, 2015:

Astellas Pharma to Acquire Ocata Therapeutics for $379 Million

Ocata was previously named Advanced Cell Technology.

December 9, 2015:

Q BioMed Licenses Glaucoma Eye Drop Candidate Being Developed by Mannin

Mannin’s lead candidate, MAN-01, is a unique molecule delivered in an eye drop formulation.

December 9, 2015:

Imprimis CEO Reveals Sales for $1 Daraprim Compound

Mark Baum unveiled a low-cost compounded version of the drug after learning of dramatic price increases by Turing.

December 9, 2015:

EHRs Could Lower Cost of FDA Clinical Trials, Califf Says at Confirmation Hearing

Califf mostly received praise, though Sen. Bernie Sanders said he was unconvinced the cardiologist would take on drug makers over high prices.

December 9, 2015:

Going Dropless? Early Results from Our Q3-2015 Survey

Preliminary data suggested that 9 percent of ophthalmic surgeons currently offer the Dropless formula.

December 9, 2015:

NICE Backs Use of Santen’s Ikervis as Dry Eye Treatment in UK

The drug, developed under the name Cyclokat, is the only ciclosporin eye drop licensed in the UK.

December 9, 2015:

Nidek Launches TONOREF III; Combo Device Incorporates Pachymeter

The unit also incorporates accommodation measurement and opacity observation of the optical media of the eye, the firm said.

December 9, 2015:

December 2015 News Briefs

Social media